CBChristiane Blecha

Christiane Blecha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christiane Blecha has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Barbara Holler

    Department of Hematology and Oncology, University Medical Center Regensburg, Regensburg, Germany

    1 shared publication
  • Daniel Wolff

    Department of Hematology and Oncology, University Medical Center Regensburg, Regensburg, Germany

    1 shared publication
  • Daniela Weber

    Department of Hematology and Oncology, University Medical Center Regensburg, Regensburg, Germany

    1 shared publication
  • Ernst Holler

    Department of Hematology and Oncology, University Medical Center Regensburg, Regensburg, Germany

    1 shared publication
  • Horst Helbig

    Department of Ophthalmology, University Medical Center Regensburg, Regensburg, Germany

    1 shared publication
  • Regine Vogt

    Department of Ophthalmology, University Medical Center Regensburg, Regensburg, Germany

    1 shared publication

Latest Publications

  • Verification of the new grading scale for ocular chronic graft-versus-host disease developed by the German-Austrian-Swiss consensus conference on chronic GVHD

    by Christiane Blecha, Daniel Wolff, Barbara Holler, Ernst Holler, Daniela Weber, Regine Vogt, Horst Helbig, Tina Dietrich-Ntoukas

    The purpose of the study was to validate a recently proposed new grading system for ocular manifestations of chronic graft-versus-host disease (cGVHD). Diagnosis of cGVHD was based on the NIH consensus criteria. In addition, a grading scale was applied, which has been developed by the German-Austrian-Swiss Consensus Conference on Clinical Practice in cGVHD. Sixty-six patients (male n = 46, female n = 20, mean age 48 years) with ocular cGVHD were included. Application of the proposed Consensus Conference grading revealed inflammatory activity in all patients with mild (33 %), moderate (44 %), or severe inflammation (23 %). Clinical scoring by the NIH scoring system showed that 6 % of patients had mild symptoms; 59 % of patients had moderate dry eye symptoms partially affecting activities of daily living, without vision impairment; and 35 % of patients had severe dry eye symptoms significantly affecting daily activities. Clinical characterization and grading by the Consensus Conference grading scale revealed that ocular cGVHD (1) frequently leads to severe ocular surface disease based on impaired function of the lacrimal glands and involvement of cornea, conjunctiva, and lids; (2) is mostly associated with ongoing inflammatory activity; (3) often leads to functional impairment and reduced quality of life; and (4) is associated with an increased risk for severe, sight-threatening complications.